NeoGenomics reported third-quarter 2026 total revenue of $209 million, an 11% increase year-over-year, driven by a 13% rise in clinical services revenue. Adjusted EBITDA expanded to $19 million, up from $12 million in the prior-year period, while GAAP net loss narrowed to $8 million. The company raised its full-year 2026 adjusted EBITDA guidance to approximately $60 million and updated its revenue outlook. Additionally, NeoGenomics announced a leadership succession plan effective January 4, 2027, with President and COO Warren Stone becoming CEO and current CEO Tony Zook transitioning to Executive Chairman. NeoGenomics is a leading provider of oncology diagnostic solutions that enable precision medicine.
